BG100248A - Squalene synthetase inhibitors - Google Patents

Squalene synthetase inhibitors

Info

Publication number
BG100248A
BG100248A BG100248A BG10024895A BG100248A BG 100248 A BG100248 A BG 100248A BG 100248 A BG100248 A BG 100248A BG 10024895 A BG10024895 A BG 10024895A BG 100248 A BG100248 A BG 100248A
Authority
BG
Bulgaria
Prior art keywords
synthetase inhibitors
squalene synthetase
squalene
inhibitors
hypochlesterolemic
Prior art date
Application number
BG100248A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ernest Hamanaka
Joel HAWKINS
Cheryl Hayward
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG100248A publication Critical patent/BG100248A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BG100248A 1994-12-23 1995-12-21 Squalene synthetase inhibitors BG100248A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23
PCT/IB1995/000424 WO1996020184A1 (en) 1994-12-23 1995-06-02 Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors

Publications (1)

Publication Number Publication Date
BG100248A true BG100248A (en) 1996-07-31

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100248A BG100248A (en) 1994-12-23 1995-12-21 Squalene synthetase inhibitors

Country Status (26)

Country Link
US (1) US5770594A (xx)
JP (1) JPH10500702A (xx)
KR (1) KR960022510A (xx)
CN (1) CN1133287A (xx)
AU (1) AU4067795A (xx)
BG (1) BG100248A (xx)
BR (1) BR9505995A (xx)
CA (1) CA2207772A1 (xx)
CZ (1) CZ344795A3 (xx)
FI (1) FI972696A (xx)
GT (1) GT199500058A (xx)
HU (1) HUT74672A (xx)
IL (1) IL116399A0 (xx)
IS (1) IS4312A (xx)
LV (1) LV11325B (xx)
MA (1) MA23746A1 (xx)
MX (1) MX9704683A (xx)
NO (1) NO955288L (xx)
OA (1) OA10204A (xx)
PE (1) PE60096A1 (xx)
PL (1) PL311997A1 (xx)
SI (1) SI9500393A (xx)
SK (1) SK158795A3 (xx)
TN (1) TNSN95133A1 (xx)
TR (1) TR199501644A2 (xx)
WO (1) WO1996020184A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
ATE434615T1 (de) 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
WO2008121602A1 (en) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor

Also Published As

Publication number Publication date
OA10204A (en) 1996-12-18
PL311997A1 (en) 1996-06-24
CZ344795A3 (en) 1996-09-11
HU9503783D0 (en) 1996-04-29
AU4067795A (en) 1996-07-04
LV11325B (en) 1997-02-20
FI972696A0 (fi) 1997-06-23
TNSN95133A1 (fr) 1996-02-06
FI972696A (fi) 1997-06-23
IS4312A (is) 1996-06-24
KR960022510A (ko) 1996-07-18
HUT74672A (en) 1997-01-28
IL116399A0 (en) 1996-03-31
MA23746A1 (fr) 1996-07-01
PE60096A1 (es) 1996-12-28
CA2207772A1 (en) 1996-07-04
WO1996020184A1 (en) 1996-07-04
NO955288L (no) 1996-06-24
CN1133287A (zh) 1996-10-16
JPH10500702A (ja) 1998-01-20
NO955288D0 (no) 1995-12-22
SK158795A3 (en) 1997-01-08
TR199501644A2 (tr) 1996-11-21
MX9704683A (es) 1997-09-30
SI9500393A (en) 1997-04-30
GT199500058A (es) 1997-06-05
US5770594A (en) 1998-06-23
LV11325A (lv) 1996-06-20
BR9505995A (pt) 1997-12-23

Similar Documents

Publication Publication Date Title
YU15299A (sh) Farmaceutski sastavi
AU2401697A (en) 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HUT75555A (en) Lactobacillus strains of human origin, their compositions and uses thereof
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
HUT68689A (en) Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
EP0650370A4 (en) METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0973540A4 (en) INSULATION AND STRUCTURAL ENLARGEMENT OF THE CRYOSTATIC LINEAR AND CYCLO DEPSIPEPTIDE DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
BG104943A (en) Biodegradable sustained-release alginate gels
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
MX9700557A (es) Dihidrobenzofuranos.
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
ZA9710098B (en) Halogenopyrimidines.
BG103914A (en) Maintained separation of delayed gels
EP0840606A4 (xx)
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
AU640520B2 (en) Novel squalene synthetase inhibitors
BG100248A (en) Squalene synthetase inhibitors
ZA97188B (en) Disinfecting compositions and processes for disinfecting surfaces.
EP0858262A4 (en) THROMBIN INHIBITORS
PL331882A1 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes
AU6849198A (en) Neurotrypsin
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання